Treatment of hairy-cell leukemia: Current views

M. S. Tallman*, L. C. Peterson, D. Hakimian, S. Gillis, A. Polliack

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Abstract

Although hairy-cell leukemia (HCL) is uncommon, remarkable progress has been made in the treatment of patients with this disease. Because of their unique mechanisms of action, the purine analogs, 2'-deoxycoformycin (2'-DCF) and 2-chlorodeoxyadenosine (2CdA), are naturally targeted to lymphocytes and are cytotoxic to both resting and dividing cells. Both of these agents induce durable complete remissions (CRs) in the overwhelming majority of patients. Remarkably, equally high rates of durable CR are achieved in both untreated and previously treated patients. Furthermore, patients with large tumor burdens fare as well as those with minimal disease. Therefore, these agents have emerged as the treatments of choice for all patients with hairy-cell leukemia and have supplanted earlier treatments such as splenectomy and interferon-α (IFN-α). Since a single 7-day cycle of 2-CdA leads to excellent outcomes and is associated with few toxicities other than culture- negative fever, this agent is particularly attractive and may offer some advantages. However, given the indolent natural history of HCL, long-term follow-up study will be required to determine if one purine analog offers a survival advantage over the other.

Original languageEnglish (US)
Pages (from-to)155-163
Number of pages9
JournalSeminars in Hematology
Volume36
Issue number2
StatePublished - May 18 1999

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Treatment of hairy-cell leukemia: Current views'. Together they form a unique fingerprint.

Cite this